Technology | August 02, 2011

FDA Clears RX Herculink Elite Renal Stent System

August 2, 2011 – The U.S. Food and Drug Administration said it recently cleared Abbott Vascular’s RX Herculink Elite Renal Stent System.

The balloon-expandable, cobalt chromium, laser-cut stent is used to re-open narrowed regions of the renal arteries. The device comes in 12, 15 and 18 mm lengths and in diameters from 4 to 7 mm.

 

This device is indicated for use in patients with atherosclerotic disease of the renal arteries following sub-optimal percutaneous transluminal renal angioplasty of a de novo or restenotic atherosclerotic lesion located within 10 mm of the renal ostium. Suboptimal angioplasty is defined as more than 50 percent residual stenosis, more than 20 mmHg peak systolic or more than 10 mmHg mean translesional pressure gradient, flow-limiting dissection, or TIMI (thrombolysis In myocardial infarction) flow of less than 3.

In the HERCULES clinical study of 202 patients, the rate of restenosis of the artery at nine months was less in this study than the rate of restenosis reported in previous studies of renal artery stenting. Results also showed that kidney function and high blood pressure had not significantly worsened at nine months. Abbott will follow all of these patients for a total of three years to assess the long-term safety and effectiveness of the device.

 

The Herculink Elite has been commercially available in the United States as a biliary stent since March 6, 2006. In addition, the same device is sold commercially as a peripheral stent system in more than 80 countries outside the United States.

 

For more information: www.accessdata.fda.gov/cdrh_docs/pdf11/p110001a.pdf

Related Content

Videos | Stents | September 11, 2018
This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is d
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents | January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents | January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents | November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
Overlay Init